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Abstract
Background: Hepatitis B is a major health concern in Africa. The vaccine against hepatitis B virus (HBV) was introduced
into the Expanded Programme on Immunization (EPI) of Cameroon and Senegal in 2005, and of CAR (Central African
Republic) in 2008. A cross-sectional study was conducted to assess HBV immunization coverage following the vaccine’s
introduction into the EPI and factors associated with having been vaccinated.
Methods: All hospitalized children, regardless of the reasons for their hospitalization, between 3 months and 6 years of
age, for whom a blood test was scheduled during their stay and whose condition allowed for an additional 2 mL
blood sample to be taken, and who provided the parent’s written consent were included. All children anti-HBs- and
anti-HBc + were tested for HBsAg.
Vaccination coverage was assessed in three different ways: immunization card, maternal recall and serologic anti-HBs profile.
Results: 1783 children were enrolled between April 2009 and May 2010. An immunization card was only available for
24 % of the children. The median age was 21 months.
Overall HBV immunization coverage based on immunization cards was 99 %, 49 % and 100 % in Cameroon, CAR and
Senegal, respectively (p < 0,001). The immunization rate based on maternal recall was 91 %, 17 % and 88 % in
Cameroon, CAR and Senegal, respectively (p < 0,001). According to serology (anti-HBs titer≥ 10 mUI/mL and anti-HBc-),
the coverage rate was 68 %, 13 % and 46 % in Cameroon, CAR and Senegal, respectively (p < 0,001). In Senegal and
Cameroon, factors associated with having been vaccinated were: mother’s higher education (OR = 2.2; 95 % CI [1.5–3.2]),
no malnutrition (OR = 1.6; 95 % CI [1.1–2.2]), access to flushing toilets (OR = 1.6; 95 % CI [1.1–2.3]), and < 24 months old
(OR = 2.1; 95 % CI [1.3–3.4] between 12 and 23 months and OR = 2.7; 95 % CI [1.6–4.4] < 12 months). The prevalence of
HBV-infected children (HBsAg+) were 0.7 %, 5.1 %, and 0.2 % in Cameroon, CAR and Senegal, respectively (p < 0.001).
Conclusions: Assessing immunization coverage based on immunization cards, maternal recall or administrative data
could be usefully reinforced by epidemiological data combined with immunological profiles. Serology-based studies
should be implemented regularly in African countries, as recommended by the WHO. Malnutrition, lack of maternal
education and poverty are factors associated with vaccine non-compliance. The countries’ vaccination programs should
actively address these problems.
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Background
Infection with hepatitis B virus (HBV) is a public health
problem worldwide [1], with more than 350 million
chronic carriers [2], 25–30 % of whom will die from the
consequences of chronic infection [1].
In sub-Saharan Africa, contact with HBV, as measured
by the prevalence of anti-HBc antibodies, varies from 65
to 85 % [3]; HBsAg prevalence ranges from 9 to 20 %
[4], and the predominant source of HBV transmission is
horizontal [5].
Antiviral treatment can reduce morbidity and mortal-
ity, but access remains limited in developing countries.
Prevention of HBV by vaccination is a key and often the
sole control strategy [6].
The anti-HBV vaccine is well tolerated and highly im-
munogenic in all age groups [7]. In 1991, the Global
Advisory Group of the EPI (Expanded programme on
immunization) recommended integrating it into all national
immunization programmes [8]. For more than a decade,
the Global Alliance for Vaccines and Immunization (GAVI)
has actively supported HBV vaccination in eligible countries
throughout the world.
Cameroon, Central African Republic (CAR) and
Senegal present high HBV endemicity. In Cameroon, the
prevalence of HBsAg positivity varies from 7.7 % among
pregnant women [9, 10] to 25 % in children > 4 years of
age [11]. CAR reports 14 % HBsAg-positivity among
young adults [12], 15 % among hospitalized patients in
Bangui [13] and 10.6 % in rural areas [14]. In Senegal, the
HBV chronic infection prevalence varies between 7 %
among newborns [15] to 17 % among blood donors [16].
In response to WHO recommendations, Cameroon
and Senegal introduced the vaccine into their EPIs in
2005 and CAR in 2008. All three countries administer
three doses of the pentavalent vaccine (Zilbrix™, a
DTPw-HBV combination vaccine [17], in Cameroon and
CAR, QuinvaxemTM, a DTwP-HepB-Hib vaccine, in
Senegal) to infants at 6, 10 and 14 weeks of age. At the
time of our study, the monovalent HBV vaccine was not
available in the three countries, and thus infants did not
receive a birth dose, even though universal vaccination
with Hepatitis B at birth is a current recommendation [1].
We conducted a cross-sectional study in a selected
population of hospitalized children in the sub-Saharan
African capitals of Cameroon, CAR and Senegal. On the
basis of this study, we previously published an article
highlighting the low protection rate (58 %) in Senegal
compared to Cameroon (92 %) among children immu-
nized with three injections of anti-HBV vaccine and in
possession of an immunization card [18].
Here we reported results on i) HBV immunization
coverage using different methods and HBV infection in
a selected population of hospitalized children in the
capitals of Cameroon, CAR and Senegal, ii) factors
associated with having been vaccinated in Senegal and
Cameroon in this selected population.
Methods
Study population
A cross-sectional study was conducted in five children’s
hospitals: one hospital in Bangui (CAR), two in Yaoundé
(Cameroon) and two in Dakar (Senegal). Both the
Yaoundé and Dakar study sites included one pediatric
hospital treating infants from families of impoverished
socioeconomic status, and one general hospital serving a
relatively well-off population. The Bangui site was a
pediatric hospital serving children from families of all
socioeconomic levels living in the city and its outskirts.
Between April 2009 and May 2010, children aged 3
month to 6 years, hospitalized for any reason, with a
blood sample prescribed during hospitalization, health
conditions allowing an extended blood sample between
2 mL and 5 mL according to the age. Children were
consecutively enrolled after their parents or legal guard-
ians received an information notice and oral explanation
in the local language and provided a written consent.
Ethical approval
This study was approved by the Senegal Health Research
National Council, the National Ethics Committee of
Cameroon and the Scientific Committee responsible for
validation protocols and study results in Central African
Republic.
Data collection
Data collected were: i) general characteristics (age, sex,
weight), ii) clinical features (reasons for hospitalization,
vaccination records on the immunization card), iii)
socio-economic characteristics (place of residence, num-
ber of people in the household, mother’s education
(higher level: at least primary education), personal trans-
portation, electricity, running water, toilets type) and iv)
serological data (anti-HBs antibodies, anti-HBc anti-
bodies, HBsAg, HBeAg) and HBV DNA, when the child
was HBsAg-positive.
If the enrolled child’s immunization card was available,
vaccination against HBV and dates of vaccination were
recorded. Otherwise, the mother was asked about the
child’s vaccination status.
Complete vaccination was defined as having received
all three injections according to the vaccination card in
compliance with the WHO vaccination schedule (6, 10 and
14 weeks of age). Partial vaccination was defined as having
received one or two doses according to the immunization
card, regardless of the immunization schedule.
Nutritional status was estimated separately for boys
and girls by the Z-score, calculated on the weight for
age, according to WHO standards for children between
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3 and 60 months old, and to CDC standards for older
children. Moderate or severe malnutrition was defined
as a Z-score ≤ −2 SD [19–21].
HBV markers
All samples were tested for anti-HBc and quantified for
anti-HBs by Enzyme ImmunoAssay (EIA) (DiaSorin
Biomedica, Sallugia, Italy). The correlate of protection
for HBV is an anti-HBs titer ≥10 mIU/mL [22, 23]. All
children anti-HBs-negative and anti-HBc-positive were
tested for HBsAg by automated EIA (AxSYM, Abbott la-
boratories, Chicago, USA). All HBsAg-positive children’s
mothers were called by phone so that children could be
retested free of charge six months later. Viral loads were
measured by the Cobas AmpliPrep/Cobas TaqMan HBV
assay, v2.0 (Roche Diagnostics, Meylan, France) at Saint-
Louis Hospital. The limit of detection was 20 IU /mL.
Except for viral load quantification, all laboratory tests
were performed in each country.
Statistical analysis
The children’s characteristics were described as medians
and interquartile ranges (IQR) for continuous variables
and percentages for discrete variables.
For univariate and multivariate analysis, quantitative
variables were expressed as dichotomous variables using
either the median or a clinically relevant threshold.
Univariate analysis was based on the Fisher’s exact test
for discrete variables and by analysis of variance or the
Kruskal-Wallis test for continuous variables. All variables
associated with “having been vaccinated” in univariate ana-
lysis (p < 0.25) were included in a backward stepwise logis-
tic regression model. A p value of ≤0.05 was considered
statistically significant. Adequacy of the model was estab-
lished through the Hosmer Lemeshow tests. Interactions
between the variables found to be associated with “having
been vaccinated” in the univariate analysis were tested
using likelihood-ratio test. Our data on immunization
coverage estimated by serological markers in children born
one year after integration of vaccine into EPI (2005 in
Cameroon and Senegal, and 2008 in CAR) were compared
with data reported by WHO on immunization coverage of
surviving infants between 2006 and 2009 [24–26].
Data were analyzed using STATA software version
12.0 (Stata Corporation, College Station, Texas).
Selected populations for analysis
Using the only publication showing that it is possible to
distinguish between the passive transfer of maternal
anti-HBc and HBV exposure in children ≥12 months
[27], we divided subjects between children younger than
12 months and those older than 12 months.
1) To evaluate the anti-HBV vaccination coverage from
serology analysis, anti-HBs + and anti-HBc + children
< 12 months were removed: their vaccination status
could not be determined, since anti-HBs antibodies
can be derived from the mother. Anti-HBs + and
anti-HBc- children, regardless of age, were considered
vaccinated and protected for an anti-HBs level
titer ≥10 mIU/mL, assuming that most sub-Saharan
African mothers were unvaccinated [10].
2) To evaluate vaccination coverage by combining
serology and vaccination card documentation: those
considered to be vaccinated were children with
serological protection (anti-HBs titer ≥10 mIU/mL),
as well as children who were unprotected based on
serology, but who had received a complete HBV
vaccination according to their immunization cards.
3) To evaluate factors associated with having been
vaccinated against HBV (regardless of serological
status, protection or non-protection): an analysis
was conducted in Cameroon and Senegal for
children born in 2006 and after, i.e., at least one
year after the integration of the HBV vaccine into
the EPIs. CAR children were not included because
the vaccine was integrated later. The variable
“vaccinated” implied having received a complete HBV
vaccination according to the immunization card, or
if no immunization card existed, by anti-HBs + and
anti-HBc- status (with anti-HBs titer ≥10mIU/mL).
All anti-HBs + and anti-HBc + children with no
immunization card were removed because we could
not know whether they were vaccinated but not
protected, or if they were not vaccinated at all.
4) HBV current infection was estimated by the number
of children with HBsAg-positivity.
Results
General characteristics of the children
A total of 1783 children were recruited: 763 in Cameroon,
535 in CAR and 485 in Senegal. No mothers of eligible
children refused to participate in the study.
General characteristics of the children are summarized
in Table 1. Forty-four percent of the children were female,
and the median age was 21 months [12–36 months]; chil-
dren were significantly older in CAR.
The main causes of the children’s hospitalization were
other infectious syndrome (33 %) and gastro-intestinal
infections (23 %) in Cameroon; malaria in CAR (54 %);
and respiratory infections (28 %) and other reasons
(35 %) in Senegal.
Immunization cards were available for 24 % of all chil-
dren. Senegalese subjects possessed a higher percentage
of immunization cards (43 %) compared to those in
Cameroon (23 %) and CAR (8 %), (p < 0.001). Among
the 1355 children without an available immunization
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card, maternal recall of HBV immunization was docu-
mented for 636 children (79, 460 and 97 children in
Cameroon, CAR and Senegal, respectively).
In Senegal, 51 % of the mothers had received primary or
secondary education, compared to 99 % in Cameroon and
92 % in CAR (p < 0.001). Senegalese children suffered
significantly more from malnutrition (46 %) than in
Cameroon (14 %) and CAR (13 %), (p < 0.001). In CAR,
families lived under poorer conditions than elsewhere.
Comparisons between the two Cameroonian hospitals
and between the two Senegalese hospitals confirm the
different socioeconomic levels of the populations served.
For instance, at one Cameroonian hospital, 65 % (173/
265) of the families had indoor flushing toilets, whereas
only 31 % (154/496) of those at the other hospital had
them. Similarly, in Senegal, 50 % (21/42) of patients at-
tending one hospital came from families with indoor
flushing toilets, compared with just 15 % (65/443) at the
other. Concerning access to running water, our results
resembled those pertaining to indoor flushing toilets: the
two Cameroonian hospitals serving 72 % (190/265) com-
pared to 39 % (192/497) of families whose homes had
piped water. Overall, our subjects came from a wide
range of families, from well-off functionary families to
very poor ones.
HBV serological markers
HBV serological markers are summarized in Table
2. Forty-two percent (755/1783) of children were anti-
HBs titer ≥10 mIU/mL and anti-HBc-: Cameroon had a
significantly higher percentage than did CAR and
Senegal (63 %, 13 % and 42 %, respectively, p < 0.001).
Thirty-eight percent (682/1783) of children were anti-
HBs titer <10 mIU/mL and anti-HBc-. Cameroon and
Senegal had a significantly lower proportion of children
anti-HBs titer <10 mIU/ml and anti-HBc- (23 % and
36 %, respectively), compared to the 62 % of children
observed in CAR, p < 0.001).
Among the 346 children anti-HBc+, 33 were HBsAg-
positive. The remaining 313 children were anti-HBs titer ≥10
mIU/mL and anti-HBc + (n= 180), or anti-HBs titer <10
mIU/mL and anti-HBc+, HBsAg-negative (n= 133). Sixty
percent (188/313) of these children were ≥12 months.
Table 1 Characteristics of children and their families
Cameroon n = 763 CAR n = 535 Senegal n = 485 Total n = 1783 p
Sex, female 329 (43) 247 (46) 212 (44) 788 (44) 0.54
Age (months) a 13 17 [10; 33] 27 [19; 37] 20 [10; 36] 21 [12; 36] <0.001
Immunization card (availability) 123 177 (23) 41 (8) 210 (43) 428 (24) <0.001
Completeb 166 (22) 13 (2) 172 (35) 351 (20) <0.001
Partialc 10 (1) 7 (1) 38 (8) 55 (3)
Moderate or severe malnutrition23 (yes) 104 (14) 68 (13) 225 (46) 397 (23) <0.001
Reasons for hospitalisation <0.001
Gastro-intestinal infection 172 (23) 103 (19) 108 (22) 383 (21)
Respiratory infection 117 (15) 42 (8) 137 (28) 296 (17)
Malaria 91 (12) 289 (54) 12 (2) 392 (22)
Other infectious syndrome 253 (33) 39 (7) 59 (12) 351 (20)
Other 130 (17) 62 (12) 169 (35) 361 (20)
Place of residence 123 (capital) 723 (95) 441 (82) 127 (26) 1291 (72) <0.001
No of people per householda 123 6 [4; 8] 8 [5; 10] 12 [7; 18] 7 [5; 10] <0.001
Household≥ 7 people 123 287 (38) 329 (62) 367 (76) 983 (55) <0.001
Mother’s education 123 (higher leveld) 751 (99) 489 (92) 242 (51) 1482 (84) <0.001
Personal transportation 13 (Car or motorcycle) 149 (20) 48 (9) 70 (14) 267 (15) <0.001
Electricity (yes) 123 754 (99) 227 (42) 424 (87) 1405 (79) <0.001
Running water (yes) 123 382 (50) 62 (12) 411 (85) 855 (48) <0.001
Flushing toilets inside house 123 (yes) 327 (43) 18 (3) 86 (18) 431 (24) <0.001
a Median [IQ1; IQ3]
b three injections in the immunization schedule
c at least one injection
d at least primary education
1: significant difference between Cameroon and CAR (p ≤ 0.05)
2: significant difference between Cameroon and Senegal (p ≤ 0.05)
3: significant difference between Senegal and CAR (p ≤ 0.05)
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Vaccination coverage according to immunization card,
maternal recall and serology
HBV vaccination coverage according to immuni-
zation card, maternal recall or serology are shown in
Table 3. Among these 428 children who had an
immunization card, 9 were vaccinated outside of the of-
ficial vaccination programme (EPI) (7 with complete
vaccination and 2 with partial vaccination). Almost all
Cameroonian and Senegalese children had been vacci-
nated (with partial or complete vaccination) (99 % and
100 %, respectively), exceeding that of CAR (49 %). Chil-
dren with an immunization card tended to be younger,
13 months versus 21 months for the entire study popu-
lation, (p = 0.006).
The delay between vaccination doses revealed adher-
ence to the recommended schedule: the median time be-
tween birth and the first vaccine dose was 47 days (28-
66); between the first and second dose, 32 days (28- 29);
and between the second and third dose, 32 days (29, 30).
Among the children vaccinated according to the
immunization card, Cameroon displayed the highest per-
centage of children with complete vaccination (94 %
(166/176) against 65 % (13/20) in CAR and 82 % (172/
210) in Senegal. Seventy-four percent (301/406) had an
anti-HBs titer ≥10 mIU/mL (89 %, 85 % and 61 % in
Cameroon, CAR and Senegal, respectively).
On the basis of the 636 maternal recalls, estimates of
immunization coverage reached 37 % overall. In Cameroon
and Senegal, coverage (91 % and 88 %, respectively) was
substantially higher than in CAR, p < 0.001.
Seventy percent (166/237) of children reported as vac-
cinated by their mothers were protected based on sero-
logical data (anti-HBs titer ≥10 mIU/mL): 75 % in
Cameroon, 59 % in CAR and 76 % in Senegal.
To estimate the immunization coverage from serological
results, 93 anti-HBs + and anti-HBc + children < 12months
were removed: their vaccination status could not be deter-
mined since anti-HBs antibodies can be derived from the
mother. On the basis of only serological results (anti-HBs
titer ≥10 mIU/mL and anti-HBc-), overall immunization
coverage was 45 % (755/1690). In Cameroon, coverage
(68 %) was significantly higher than in CAR (13 %) and
Senegal (46 %), (p <0.001). When immunization cover-
age was estimated both for serological results as defined
above and, for children who were unprotected based on
serology, from complete HBV vaccination according to
Table 2 HBV serological markers N (%)
Cameroon n = 763 CAR n = 535 Senegal n = 485 Total n = 1783 p
Anti-HBc- (N = 1437) Anti-HBs≥ 10 mIU/mL 482 (63) 67 (13) 206 (42) 755 (42) <0.001
Anti-HBs < 10 mIU/mL 176 (23) 331 (62) 175 (36) 682 (38) <0.001
Anti-HBc + (N = 346) Anti-HBs≥ 10 mIU/mL 80 (10) 35 (7) 65 (13) 180 (10) 0.001
Anti-HBs < 10 mIU/mL 25 (3) 102 (19) 39 (8) 166 (10) <0.001
- HBsAg-positive 5 27 1 33
- HbsAg-negative 20 75 38 133
Table 3 HBV vaccination coverage according to immunization card, maternal recall or serology: n/N (%)
Cameroon n = 763 CAR n = 535 Senegal n = 485 Total n = 1783 p
Immunization card (availability) 123 177 (23) 41 (8) 210 (43) 428 (24) <0.001
Vaccinated123a 176/177 (99) 20/41 (49) 210/210 (100) 406/428 (95) <0.001
Complete vaccinationb 166 13 172 351
Partial vaccinationc 10 7 38 55
Anti-HBs titer ≥10 mIU/mL 156/176 (89) 17/20 (85) 128/210 (61) 301/406 (74)
Maternal recall 123 d 72/79 (91) 80/460 (17) 85/97 (88) 237/636 (37) <0.001
Anti-HBs titer ≥10 mIU/mL 54/72 (75) 47/80 (59) 65/85 (76) 166/237 (70)
Serology 123 (Anti-HBs titer ≥10 mIU/mL12 and Anti-HBc-) e 482/712 (68) 67/534 (13) 206/444 (46) 755/1690 (45) <0.001
Immunization card (complete vaccination) or serology f 527/737 (72) 68/535 (13) 294/467 (63) 889/1739 (51) <0.001
a received at least one dose injection
b received all three doses injections
c received one or two doses injections
d documented for 636 children without available immunization card
e children < 12 months excluded (n = 93)
f children < 12 months without available immunization card excluded (n = 44)
1: significant difference between Cameroon and CAR (p ≤ 0.05)
2: significant difference between Cameroon and Senegal (p ≤ 0.05)
3: significant difference between Senegal and CAR (p ≤ 0.05)
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immunization cards, vaccination coverage reached 51 %
(889/1739) (44 children were excluded because they
were anti-HBs + and anti-HBc + < 12 months without
immunization card).
While the two approaches led to similar results in
Cameroon and CAR, a difference of 17 % (46 % versus
63 %) was observed between the two estimates in Senegal.
HBV immune protection (anti-HBs titer ≥10 mIU/mL
among anti-HBc-) according to year of birth and country
and comparisons with WHO estimates
The percentages of children serologically protected
gradually increased between 2006 and 2009 from 63 %
(47/75) to 82 % (151/185) in Cameroon and from 2 %
(2/83) to 50 % (27/54) in CAR. In Senegal, however, the
percentage of children serologically protected fluctuated
between 42 % (24/57) and 50 % (52/103) during these
same years (Fig. 1).
Factors associated with the fact of having been
vaccinated
In Cameroon and Senegal, four factors were identified
as independently associated with having been vaccinated:
mother’s higher level of education (OR = 2.2), no malnu-
trition (OR = 1.6), access to flushing toilets (OR = 1.6),
and being <24 months old (OR = 2.1 between 12 and
23 months and OR = 2.7 < 12 months) (Table 4). There
was no evidence for the interactions between the vari-
ables associated with having been vaccinated.
HBV infections
The percentage of HBV-infected children was significantly
lower in Cameroon [0.7 % (5/763)] and Senegal [0.2 %
(1/485)] compared to CAR [5.1 % (27/535)] (p < 0.001).
The overall median viral load was 8 log IU/mL. Among
the 27 HBsAg-positive children in CAR, 14 (52 %) were
IgM anti-HBc + and 20 (74 %) were HBeAg-positive.
Among the twelve children who returned six months later,
six were HBsAg-positive. In Cameroon and Senegal,
among the six HBsAg-positive children, the two children
who returned six months later were confirmed to be
HBsAg-positive. In CAR, 20 out of 27 infected children
were ≥24 months, indicating that they were infected be-
fore the HBV vaccine’s introduction into the EPI. Among
the seven children <24 months, only one 15 months old
child possessed an immunization card documenting that
he was not vaccinated. No information about the vaccin-
ation status of six other children was available, but all
were born before September 2008. In Cameroon, among
the five children HBsAg-positive, only one was under
24 months old; no information about the child’s vaccine
status was available. The other four children were born
prior to July 2005. The only Senegalese child infected was
born at the end of 2006.
Discussion
Immunization coverage was estimated using different
methods: the immunization card, maternal recall and
serological profile, and a combination of immunization


























Fig. 1 HBV immune protection (anti-HBs +≥10 mIU/ml among anti-HBc-) according to the year of birth and the country compared to WHO
coverage estimates. Y axis: percentage of immunized children
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serology showed higher coverage in Cameroon (68 %)
and Senegal (46 %) than in CAR (13 %), because of the
very recent introduction of the HBV vaccine in CAR. In
Cameroon and CAR, the percentage of children immu-
nized and protected increased over time from 2006 to
2009. This increased coverage relates to the level of in-
vestment and time required to set up the necessary de-
livery infrastructures and to reach isolated areas [31]. In
both countries, results based on both vaccination and
anti HBs profile convene closely to those based exclu-
sively on serology, confirming that children vaccinated
according to the immunization cards are protected.
In Senegal, the percentage of children vaccinated and
protected fluctuated over time, with a maximum of 50 %
in 2009 and a minimum of 38 % in 2007. If the results of
subjects’ immunization cards are factored in, some chil-
dren vaccinated according to the immunization cards
were not, in fact, protected. Possible hypotheses for this
lack of response to the vaccine, including storage condi-
tions, cold chain issues or immunogenicity of the differ-
ent vaccines, were previously reported [18].
The WHO/UNICEF, in assessing national immunization
coverage of surviving infants, draws from several informa-
tion sources: administrative data (reports from vaccination
services), official data (the best estimates from authorities,
which account for administrative data and any other avail-
able information) and monitoring survey data [29]. As
shown in Fig. 1, in Cameroon, immunization coverage rates
reported by the WHO for 2006–2009 (81 % to 88 %) are
close to our results [23]. Similarly, in CAR, the WHO esti-
mated coverage at 42 % in 2009, a rate similar to our results
[24]. In Senegal, the WHO, relying on administrative and
official data, estimated coverage at 89 % in 2006, 94 % in
2007, and 88 % in 2008 [25]. Serological analysis in our
study produced substantially lower results. An external re-
view of the EPI and a MICS (Multiple Indicator Cluster
Survey) was carried out in Senegal in 2009 and reported
immunization coverage of 74 % and 83 %, but the WHO
did not use the results in its final estimates. Our results
differed from WHO estimates when coverage analysis was
based on serology results (50 %). These disparities may
have different explanations. The WHO has noted that
administrative data are subject to biases that can distort
immunization coverage calculations [29], for example,
when they include all vaccines delivered to vaccination
centres, and not just vaccinations among children adhering
to the immunization schedule [32]. Although vaccination
is free, non-adherence to vaccination occurs in Senegal and
Cameroon. We identified four factors associated with hav-
ing been vaccinated against HBV (regardless of protection):
mother’s higher education, having access to indoor flushing
toilets, a child not being malnourished and being younger.
The gradual increase in coverage following the vaccine’s
introduction explains the association with age. Some stud-
ies have shown a link between mother’s education and ac-
ceptance of immunization [33]. Regarding the association
between non-vaccination and malnutrition, studies have
established a link between poor health and delayed vaccin-
ation of children [34–36]. The association with lack of in-
door flushing toilets can be explained by families’ lower
socio-economic status, entailing, for example, distance to a
vaccination centre and transport costs [30].
The low rate of HBsAg carriers (0.7 % in Cameroon
and 0.2 % in Senegal) suggests the effectiveness of the
Table 4 Factors associated with having been vaccinated for children born in 2006 or later in Cameroon or Senegal
N (%) Non-vaccinateda Vaccinatedb Univariate analysis Multivariate analysis
(n = 244) (n = 731) OR [CI95%] P OR [CI95%] p
Mother’s education
No education 79 (33) 101 (14) 1 1
Higher education (at least elementary) 161 (67) 625 (86) 3.0 [2.2;4.3] <0.001 2.2 [1.5;3.2] <0.001
Nutritional status
Malnutrition 93 (39) 169 (24) 1 1
No malnutrition 147 (61) 539 (76) 2.0 [1.5;2.8] <0.001 1.6 [1.1;2.2] 0.011
Age
<12 months 67 (27) 269 (37) 2.5 [1.5; 3.9] <0.001 2.7 [1.6;4.4] <0.001
[12–24] 81 (33) 271 (37) 2.0 [1.3; 3.2] 0.002 2.1 [1.3;3.4] 0.003
[24–36] 55 (23) 124 (17) 1.4 [0.8; 2.3] 0.21 1.4 [0.8;2.4] 0.21
≥36 months 41 (17) 67 (9) 1 1
Toilets
Without flushing 190 (78) 453 (62)) 1 1
With flushing 54 (22) 277 (38) 2.2 [1.5;3.0] <0.001 1.6 [1.1;2.3] 0.009
a Children anti-HBs- and anti-HBc- or anti-HBs- and anti-HBc+
b Children anti-HBs + and anti-HBc-, or based on the immunization card, with complete vaccination
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countries’ EPIs and of GAVI’s support for HBV vaccin-
ation in these two countries. Nevertheless, a significant
number of children who are 12 months or more (220/
1348); 9 % (46/527) in Cameroon and 13 % (45/341) in
Senegal came into contact with the virus (anti-HBc+),
suggesting the importance of improving hepatitis B vac-
cine coverage. Moreover, as recommended by the WHO,
advancing the first dose within 24 h of birth could fur-
ther reduce contact with the virus in these populations.
Our study has limitations. This hospitalized-based
population from whom a blood sample was collected
does not constitute a representative sample and cannot
be considered representative of the entire child popula-
tion. Unlike studies using nationally representative data
from the household-based Demographic and Health Sur-
veys (DHS) or two-stage cluster sampling methodology,
we have studied only children hospitalized in five hospi-
tals in three capitals. The selected hospitals, which serve
different socioeconomic populations, probably do not
significantly over- or underestimate immunization cover-
age and the generalizability of the serological findings.
But it remains difficult to determine how much these
findings differ from immunization coverage among rural
populations. Canavan et al. recently show that in East
Africa, urban residence is associated with increased odds
of complete vaccination status [28].
The selection of hospitalized children, including 23 % of
moderate or severe malnourished children may also have
affected these estimates. In addition, the cross-sectional
design allows us to draw conclusions about associations
with complete vaccination, but causality cannot be ascer-
tained from our data. Serology estimates did not account
for children with anti-HBs + and anti-HBc + under
12 months old (93/1783). However, 53 % (49/93) of these
children had an immunization card documenting them as
vaccinated. We argue that the exclusion of 44 children
had a limited impact on our overall results. In contrast,
the strength of our study is that our Pasteur team evalu-
ated the serological markers of samples from children ad-
mitted to the five capital city hospitals.
Conclusion
Five years after the integration of the hepatitis B vaccine
in their EPI, vaccination programmes must persist in im-
proving vaccination coverage. Assessing immunization
coverage based on immunization cards, maternal recall or
administrative data could be usefully reinforced by epi-
demiological data combined with immunological profiles.
Serology-based studies should be implemented regularly
in African countries, as recommended by the WHO.
Among the African populations studied, malnutrition, lack
of maternal education and poverty are factors associated
with vaccine non-compliance. The countries’ vaccination
programs should actively address these problems.
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